.png)
BioCorRx Pharmaceuticals, Inc is a biopharmaceutical company and a subsidiary of BioCorRx Inc. specializing in developing treatments for substance use disorder. The company is seeking FDA approval for a naltrexone pellet, called BICX104, for the treatment of alcohol and opioid use disorders (AUD and OUD). The product is designed to last 3 months once subcutaneously implanted under the skin in the lower abdominal area by a very simple outpatient procedure that can be done in a doctor’s office.
BICX104 completion of its first in human study was March 22, 2023. Final study reports are in progress but interim data show that BICX104 is well tolerated and can achieve therapeutic naltrexone levels up to 84 days.
